165 related articles for article (PubMed ID: 34509803)
1. Priorities and preferences of advanced soft tissue sarcoma patients starting palliative chemotherapy: baseline results from the HOLISTIC study.
Younger E; Jones RL; den Hollander D; Soomers VLMN; Desar IME; Benson C; Young RJ; Oosten AW; de Haan JJ; Miah A; Zaidi S; Gelderblom H; Steeghs N; Husson O; van der Graaf WTA
ESMO Open; 2021 Oct; 6(5):100258. PubMed ID: 34509803
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality Of Life
Younger E; Jones RL; Desar IME; Peckitt C; van der Graaf WTA; Husson O
BMJ Open; 2020 Jun; 10(6):e035171. PubMed ID: 32487574
[TBL] [Abstract][Full Text] [Related]
3. Cancer patient preferences for quality and length of life.
Meropol NJ; Egleston BL; Buzaglo JS; Benson AB; Cegala DJ; Diefenbach MA; Fleisher L; Miller SM; Sulmasy DP; Weinfurt KP;
Cancer; 2008 Dec; 113(12):3459-66. PubMed ID: 18988231
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials.
Younger E; Litière S; Le Cesne A; Mir O; Gelderblom H; Italiano A; Marreaud S; Jones RL; Gronchi A; van der Graaf WTA
Oncologist; 2018 Oct; 23(10):1250-1259. PubMed ID: 29650688
[TBL] [Abstract][Full Text] [Related]
5. Does palliative chemotherapy really palliate and are we measuring it correctly? A mixed methods longitudinal study of health related quality of life in advanced soft tissue sarcoma.
Gough N; Koffman J; Ross JR; Riley J; Judson I
PLoS One; 2019; 14(9):e0210731. PubMed ID: 31557183
[TBL] [Abstract][Full Text] [Related]
6. Quality of life versus length of life considerations in cancer patients: A systematic literature review.
Shrestha A; Martin C; Burton M; Walters S; Collins K; Wyld L
Psychooncology; 2019 Jul; 28(7):1367-1380. PubMed ID: 30838697
[TBL] [Abstract][Full Text] [Related]
7. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients.
Karavasilis V; Seddon BM; Ashley S; Al-Muderis O; Fisher C; Judson I
Cancer; 2008 Apr; 112(7):1585-91. PubMed ID: 18278813
[TBL] [Abstract][Full Text] [Related]
8. Decisional control preferences of patients with advanced cancer receiving palliative care.
Tricou C; Yennu S; Ruer M; Bruera E; Filbet M
Palliat Support Care; 2018 Oct; 16(5):544-551. PubMed ID: 29094668
[TBL] [Abstract][Full Text] [Related]
9. Social and clinical determinants of preferences and their achievement at the end of life: prospective cohort study of older adults receiving palliative care in three countries.
Higginson IJ; Daveson BA; Morrison RS; Yi D; Meier D; Smith M; Ryan K; McQuillan R; Johnston BM; Normand C;
BMC Geriatr; 2017 Nov; 17(1):271. PubMed ID: 29169346
[TBL] [Abstract][Full Text] [Related]
10. Older adults' preferred and perceived roles in decision-making about palliative chemotherapy, decision priorities and information preferences.
Moth EB; Kiely BE; Martin A; Naganathan V; Della-Fiorentina S; Honeyball F; Zielinski R; Steer C; Mandaliya H; Ragunathan A; Blinman P
J Geriatr Oncol; 2020 May; 11(4):626-632. PubMed ID: 31439474
[TBL] [Abstract][Full Text] [Related]
11. Outcome of chemotherapy in advanced synovial sarcoma patients: Review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entity.
Vlenterie M; Litière S; Rizzo E; Marréaud S; Judson I; Gelderblom H; Le Cesne A; Wardelmann E; Messiou C; Gronchi A; van der Graaf WT
Eur J Cancer; 2016 May; 58():62-72. PubMed ID: 26968015
[TBL] [Abstract][Full Text] [Related]
12. Decisional control preferences, disclosure of information preferences, and satisfaction among Hispanic patients with advanced cancer.
Noguera A; Yennurajalingam S; Torres-Vigil I; Parsons HA; Duarte ER; Palma A; Bunge S; Palmer JL; Bruera E
J Pain Symptom Manage; 2014 May; 47(5):896-905. PubMed ID: 24035071
[TBL] [Abstract][Full Text] [Related]
13. Managing patients with advanced soft tissue sarcoma: Evolving landscape from an Australian perspective.
Bae S; Brnabic A; Crowe P; Carey-Smith R; Andelkovic V; Singhal N; Stalley P; Yip D; Desai J
Asia Pac J Clin Oncol; 2022 Dec; 18(6):605-613. PubMed ID: 35098667
[TBL] [Abstract][Full Text] [Related]
14. Factors affecting prognosis and treatment strategies in metastatic soft tissue sarcomas: twenty years of experience.
İlhan A; Eraslan E; Yildiz F; Arslan ÜY; Alkiş N
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(21):6465-6472. PubMed ID: 34787850
[TBL] [Abstract][Full Text] [Related]
15. Quality of life and added value of a tailored palliative care intervention in patients with soft tissue sarcoma undergoing treatment with trabectedin: a multicentre, cluster-randomised trial within the German Interdisciplinary Sarcoma Group (GISG).
Hentschel L; Richter S; Kopp HG; Kasper B; Kunitz A; Grünwald V; Kessler T; Chemnitz JM; Pelzer U; Schuler U; Freitag J; Schilling A; Hornemann B; Arndt K; Bornhäuser M; Schuler MK
BMJ Open; 2020 Aug; 10(8):e035546. PubMed ID: 32859662
[TBL] [Abstract][Full Text] [Related]
16. Palliative chemotherapy or best supportive care? A prospective study explaining patients' treatment preference and choice.
Koedoot CG; de Haan RJ; Stiggelbout AM; Stalmeier PF; de Graeff A; Bakker PJ; de Haes JC
Br J Cancer; 2003 Dec; 89(12):2219-26. PubMed ID: 14676798
[TBL] [Abstract][Full Text] [Related]
17. Patients' perception of the benefits of palliative systemic therapy for advanced cancer.
Subramaniam S; Adams DH; Tognela A; Roncolato F; Yip PY; Lim SH; Roohullah A; Stockler MR; Kiely B
Intern Med J; 2024 May; 54(5):735-741. PubMed ID: 38205872
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
[TBL] [Abstract][Full Text] [Related]
19. Absence of progression, not extent of tumour shrinkage, defines prognosis in soft-tissue sarcoma - An analysis of the EORTC 62012 study of the EORTC STBSG.
Grünwald V; Litière S; Young R; Messiou C; Lia M; Wardelmann E; van der Graaf W; Gronchi A; Judson I;
Eur J Cancer; 2016 Sep; 64():44-51. PubMed ID: 27323349
[TBL] [Abstract][Full Text] [Related]
20. Patient preferences for palliative treatment of locally advanced or metastatic gastric cancer and adenocarcinoma of the gastroesophageal junction: a choice-based conjoint analysis study from Germany.
Hofheinz R; Clouth J; Borchardt-Wagner J; Wagner U; Weidling E; Jen MH; Brück P
BMC Cancer; 2016 Dec; 16(1):937. PubMed ID: 27923357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
